Traders News Source Initiates Coverage on JanOne Inc. (NASDAQ: JAN), a Biotech Company with a Lead Product to Combat Covid-19
JanOne (JAN) Makes a Case For its Lead Product to Combat Covid 19
Tiny float stock with a big book value
Good day everyone,
We are initiating coverage on JanOne Inc. (NASDAQ: JAN), a company focused on bringing medications to market to treat diseases that cause severe pain.
Current price $4.40 per share
Outstanding shares (est.) 1.99M
Float (est.) 1.35M
Insider ownership 52.97%
Book value (mrq) $8.71 per share
Market cap $7.7M
JAN shares gained 35% Thursday on news it has entered into an agreement with CATO SMS, a regulatory and clinical contract research organization. CATO SMS will assist JanOne in expanding its current FDA authorized Investigational New Drug (IND) for JAN101, an oral, sustained release formulation of sodium nitrite, to treat vascular complications to potentially restore endothelial cell function in COVID-19 patients. Trading volume of 2.3M shares exceeded the company share count.
In addition, JAN101 is expected to enter Phase 2b trials in early 2021 to treat Peripheral Artery Disease (PAD).
It is rare to see a pharma company that is developing a potential treatment for covid 19 with a market cap less than $10M. JAN is working toward a world free from opiates on two fronts, developing drugs to treat ailments that cause pain, and developing an opiate free pain medication.
JAN acquired the worldwide right to TV1001SR, a twice-daily orally dosed slow-release formulation of the FDA-approved therapeutic sodium nitrite
The company renamed the product JAN101 and it is their lead product. Results from Phase 2a clinical trials support the use of sodium nitrite for the treatment and prevention of Peripheral Artery Disease (PAD), and as a non-addictive treatment for Diabetic Neuropathy.
Peripheral Artery Disease (PAD) is a chronic disorder associated with reduced blood flow to the extremities. PAD often causes severe pain in the extremities, limits mobility, and in some cases may lead to death. In the US alone, PAD affects nearly 12 million people, and if left untreated will lead to Critical Limb Ischemia with an annual cost of care estimated at $10 billion. 1 in every 20 adults over the age of 50 years, and 1 in every 4 adults over the age of 70 years are likely to develop PAD.
The case for JAN101 in the treatment of Covid 19:
A recent study published in the New England Journal of Medicine3 indicates the possibility that the respiratory complications from COVID-19 may originate from restrictions and damage to the vascular system and endothelial cell dysfunction. The implication is that the endothelial cells that line the blood vessels are severely compromised and limit the body’s ability to carry oxygen to major organs in the body, including the lungs. Previous JAN101 clinical studies have shown promise in repairing and restoring vascular function with minimal adverse events, which may potentially prove to be beneficial to COVID-19 patients.
“If COVID-19 is, in fact, a vascular disease that attacks endothelial cells restricting the ability of cells to deliver oxygen to vital organs, our sodium nitrite tablets could potentially offer a safe and effective treatment for that aspect of the disease,” said Tony Giordano, PhD, JanOne’s chief scientific officer.
Potential catalysts and positives for JAN:
Protocols established for the 2B clinical trial for PAD
Further studies on the potential for JAN101 to impact Covid 19.
There are only 1.35M shares in the float making a significant gain a greater possibility.
The book value is much higher than the share price.
Insiders own 52.97% of the shares and have a vested interest in the company’s success.
JAN had revenue (ttm) of $37M.
JanOne has moved quickly to exploit JAN101 by adding scientific stall and creating a scientific advisory board. JAN is a company with a tiny ($7.7M) market cap that may not stay at that level long. As investor awareness of the company grows, so could its market cap.
Note in the chart linked below that JAN shares have crossed their 50 DMA and 200 DMA of $3.40 and $3.05 respectively in a bullish manner. https://stockcharts.com/h-sc/ui?s=JAN
More on JanOne coming soon…
The Traders News Group
Do we disclose any information to outside parties?
We hate spam and we do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form. This includes your email address only.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address
What do we use your information for?
When we collect your email it is used for one purpose to send you the free information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use a secure third party to send email to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. TNS LLC’s parent company has been compensated sixteen thousand five hundred dollars cash via bank wire by venado media llc for this weeks mention of jan. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.